CD5 📈 Amundi Index Solutions - - Overview
Exchange: PA • Country: France • Currency: EUR • Type: Etf • ISIN: LU1681047319 • Eurozone Large-Cap Equity
CD5: Equities, Stocks, Index, Tracking, Europe
The investment seeks to track the performance of EURO STOXX 50 Index, and to minimize the tracking error between the net asset value of the sub-fund and the performance of the Index ‣ Company URL: https://first-eagle.amundi.com/ ‣ Domicile: Luxembourg ‣ Index Name: Morningstar Dev Ezn TME NR EUR
Additional Sources for CD5 ETF
CD5 ETF Overview
| Market Cap in USD | 667m |
| Category | Eurozone Large-Cap Equity |
| TER | 0.09% |
| IPO / Inception | 2018-02-14 |
CD5 ETF Ratings
| Growth 5y | 55.9% |
| Fundamental | - |
| Dividend | 27.5% |
| Rel. Strength Industry | 143 |
| Analysts | - |
| Fair Price Momentum | 75.48 EUR |
| Fair Price DCF | - |
CD5 Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 91.6% |
CD5 Growth Ratios
| Growth Correlation 3m | -24.4% |
| Growth Correlation 12m | 36.8% |
| Growth Correlation 5y | 89.5% |
| CAGR 5y | 7.97% |
| CAGR/Mean DD 5y | 1.16 |
| Sharpe Ratio 12m | 0.50 |
| Alpha | -9.61 |
| Beta | 0.75 |
| Volatility | 10.84% |
| Current Volume | 18.9k |
| Average Volume 20d | 6.7k |
What is the price of CD5 stocks?
As of December 22, 2024, the stock is trading at EUR 76.64 with a total of 18,922 shares traded.
Over the past week, the price has changed by -1.82%, over one month by +2.79%, over three months by -0.94% and over the past year by +10.69%.
As of December 22, 2024, the stock is trading at EUR 76.64 with a total of 18,922 shares traded.
Over the past week, the price has changed by -1.82%, over one month by +2.79%, over three months by -0.94% and over the past year by +10.69%.
Is Amundi Index Solutions - a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Amundi Index Solutions - (PA:CD5) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 55.89 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CD5 as of December 2024 is 75.48. This means that CD5 is currently overvalued and has a potential downside of -1.51%.
Partly, yes. Based on ValueRay Analyses, Amundi Index Solutions - (PA:CD5) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 55.89 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CD5 as of December 2024 is 75.48. This means that CD5 is currently overvalued and has a potential downside of -1.51%.
Is CD5 a buy, sell or hold?
Amundi Index Solutions - has no consensus analysts rating.
Amundi Index Solutions - has no consensus analysts rating.
What are the forecast for CD5 stock price target?
According to ValueRays Forecast Model, CD5 Amundi Index Solutions - will be worth about 83.3 in December 2025. The stock is currently trading at 76.64. This means that the stock has a potential upside of +8.64%.
According to ValueRays Forecast Model, CD5 Amundi Index Solutions - will be worth about 83.3 in December 2025. The stock is currently trading at 76.64. This means that the stock has a potential upside of +8.64%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 83.3 | 8.6% |